• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-221 促进人三阴性乳腺癌细胞的肿瘤发生。

miR-221 promotes tumorigenesis in human triple negative breast cancer cells.

机构信息

Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America.

出版信息

PLoS One. 2013 Apr 24;8(4):e62170. doi: 10.1371/journal.pone.0062170. Print 2013.

DOI:10.1371/journal.pone.0062170
PMID:23637992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3634767/
Abstract

Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis. TNBCs are characterized by their resistance to apoptosis, aggressive cellular proliferation, migration and invasion, and currently lack molecular markers and effective targeted therapy. Recently, miR-221/miR-222 have been shown to regulate ERα expression and ERα-mediated signaling in luminal breast cancer cells, and also to promote EMT in TNBCs. In this study, we characterized the role of miR-221 in a panel of TNBCs as compared to other breast cancer types. miR-221 knockdown not only blocked cell cycle progression, induced cell apoptosis, and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27(kip1). Furthermore, miR-221 knockdown inhibited cell migration and invasion by altering E-cadherin expression, and its regulatory transcription factors Snail and Slug in human TNBC cell lines. Therefore, miR-221 functions as an oncogene and is essential in regulating tumorigenesis in TNBCs both in vitro as well as in vivo.

摘要

三阴性乳腺癌(TNBC)患者通常预后不良。TNBC 的特征是对细胞凋亡、侵袭、迁移和增殖具有抵抗性,目前缺乏分子标志物和有效的靶向治疗方法。最近,miR-221/miR-222 被证明可以调节腔乳腺癌细胞中 ERα 的表达和 ERα 介导的信号转导,也可以促进 TNBC 中的 EMT。在这项研究中,我们比较了 TNBC 与其他乳腺癌类型的 panel 来研究 miR-221 的作用。miR-221 敲低不仅在体外阻断细胞周期进程、诱导细胞凋亡和抑制细胞增殖,而且通过靶向 p27(kip1) 抑制体内肿瘤生长。此外,miR-221 敲低通过改变 E-钙黏蛋白表达及其调节转录因子 Snail 和 Slug 抑制人 TNBC 细胞系中的细胞迁移和侵袭。因此,miR-221 作为癌基因发挥作用,在调节 TNBC 的体外和体内肿瘤发生中是必不可少的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/90362df05aa5/pone.0062170.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/dbfb4bbbf536/pone.0062170.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/ac806e33d0f6/pone.0062170.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/799ca8af8263/pone.0062170.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/430d641282ad/pone.0062170.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/90362df05aa5/pone.0062170.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/dbfb4bbbf536/pone.0062170.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/ac806e33d0f6/pone.0062170.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/799ca8af8263/pone.0062170.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/430d641282ad/pone.0062170.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0426/3634767/90362df05aa5/pone.0062170.g005.jpg

相似文献

1
miR-221 promotes tumorigenesis in human triple negative breast cancer cells.miR-221 促进人三阴性乳腺癌细胞的肿瘤发生。
PLoS One. 2013 Apr 24;8(4):e62170. doi: 10.1371/journal.pone.0062170. Print 2013.
2
Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition.三阴性乳腺癌衍生的微小囊泡将 microRNA221 转移至受体细胞,从而促进上皮间质转化。
J Biol Chem. 2019 Sep 13;294(37):13681-13696. doi: 10.1074/jbc.RA119.008619. Epub 2019 Jul 24.
3
MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.miR-92b 通过靶向 Gabra3 抑制细胞 EMT,预测三阴性乳腺癌患者的预后。
Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10433-10442. doi: 10.26355/eurrev_201912_19682.
4
miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer.miR-3178 通过靶向三阴性乳腺癌中的 Notch1 抑制细胞增殖和转移。
Cell Death Dis. 2018 Oct 17;9(11):1059. doi: 10.1038/s41419-018-1091-y.
5
TFAP2A downregulation mediates tumor-suppressive effect of miR-8072 in triple-negative breast cancer via inhibiting SNAI1 transcription.TFAP2A 的下调通过抑制 SNAI1 转录介导 miR-8072 在三阴性乳腺癌中的肿瘤抑制作用。
Breast Cancer Res. 2024 Jun 18;26(1):103. doi: 10.1186/s13058-024-01858-x.
6
LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702.长链非编码 RNA LUCAT1 通过调节 miR-5702 促进三阴性乳腺癌的发生发展和转移
Biosci Rep. 2019 Sep 3;39(9). doi: 10.1042/BSR20190489. Print 2019 Sep 30.
7
Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.miR-34c-3p通过调节三阴性乳腺癌细胞中的MAP3K2信号传导对癌进展和上皮-间质转化的调控
Biochem Biophys Res Commun. 2017 Jan 29;483(1):10-16. doi: 10.1016/j.bbrc.2017.01.023. Epub 2017 Jan 7.
8
miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling.miR-122-5p 通过抑制有丝分裂原活化蛋白激酶信号通路中的多泡体分选蛋白 3 促进三阴性乳腺癌的侵袭和上皮间质转化。
J Cell Physiol. 2020 Mar;235(3):2825-2835. doi: 10.1002/jcp.29188. Epub 2019 Sep 20.
9
MiR-1976 knockdown promotes epithelial-mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis.miR-1976 下调促进上皮间质转化和癌症干细胞特性,诱导三阴性乳腺癌转移。
Cell Death Dis. 2020 Jul 3;11(7):500. doi: 10.1038/s41419-020-2711-x.
10
microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.微小RNA-761通过抑制TRIM29表达诱导三阴性乳腺癌细胞的侵袭性表型。
Cell Oncol (Dordr). 2017 Apr;40(2):157-166. doi: 10.1007/s13402-016-0312-6. Epub 2017 Jan 4.

引用本文的文献

1
Non-coding RNAs as key regulators of epithelial-mesenchymal transition in breast cancer.非编码RNA作为乳腺癌上皮-间质转化的关键调节因子
Front Cell Dev Biol. 2025 Mar 25;13:1544310. doi: 10.3389/fcell.2025.1544310. eCollection 2025.
2
Construction and validation of a prognostic risk model for breast cancer based on protein expression.基于蛋白质表达构建和验证乳腺癌预后风险模型。
BMC Med Genomics. 2022 Jul 4;15(1):148. doi: 10.1186/s12920-022-01299-5.
3
The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer.

本文引用的文献

1
Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells.Slug 转录因子与 MDA-MB-231 乳腺癌细胞中 miR-221 的相关性。
BMC Cancer. 2012 Oct 2;12:445. doi: 10.1186/1471-2407-12-445.
2
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness.癌症中的 EMT 激活转录因子:超越 EMT 和肿瘤侵袭性。
Cell Mol Life Sci. 2012 Oct;69(20):3429-56. doi: 10.1007/s00018-012-1122-2. Epub 2012 Sep 4.
3
The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity.
非编码 RNA 在三阴性和四阴性乳腺癌中的功能意义及串扰。
Mol Biol Rep. 2022 Jul;49(7):6899-6918. doi: 10.1007/s11033-022-07288-2. Epub 2022 Mar 2.
4
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review.微小RNA和长链非编码RNA作为三阴性乳腺癌潜在生物标志物的综述
Front Oncol. 2020 Nov 20;10:526850. doi: 10.3389/fonc.2020.526850. eCollection 2020.
5
Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype.微小RNA在具有基底样表型的三阴性乳腺癌中的调节作用。
Cancers (Basel). 2020 Nov 7;12(11):3298. doi: 10.3390/cancers12113298.
6
MicroRNAs, a Promising Target for Breast Cancer Stem Cells.微小 RNA,乳腺癌干细胞的有前途的靶点。
Mol Diagn Ther. 2020 Feb;24(1):69-83. doi: 10.1007/s40291-019-00439-5.
7
Emerging ways to treat breast cancer: will promises be met?新兴的乳腺癌治疗方法:能否兑现承诺?
Cell Oncol (Dordr). 2018 Dec;41(6):605-621. doi: 10.1007/s13402-018-0409-1. Epub 2018 Sep 27.
8
MiRNA-221 from tissue may predict the prognosis of patients with osteosarcoma.来自组织的微小RNA-221可预测骨肉瘤患者的预后。
Medicine (Baltimore). 2018 Jul;97(29):e11100. doi: 10.1097/MD.0000000000011100.
9
MicroRNAs in regulation of triple-negative breast cancer progression.微小 RNA 在三阴性乳腺癌进展中的调控作用。
J Cancer Res Clin Oncol. 2018 Aug;144(8):1401-1411. doi: 10.1007/s00432-018-2689-2. Epub 2018 Jun 19.
10
Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities.纳米颗粒介导的治疗剂递送用于治疗转移性乳腺癌——挑战与机遇
Nanomaterials (Basel). 2018 May 24;8(6):361. doi: 10.3390/nano8060361.
miR-200 和 miR-221/222 微小 RNA 家族:对上皮特性的相反作用。
J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):65-77. doi: 10.1007/s10911-012-9244-6. Epub 2012 Feb 17.
4
Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.抗 microRNA-222(anti-miR-222)和-181B 通过靶向 TIMP3 蛋白和调节有丝分裂信号来抑制小鼠他莫昔芬耐药异种移植物的生长。
J Biol Chem. 2011 Dec 9;286(49):42292-42302. doi: 10.1074/jbc.M111.270926. Epub 2011 Oct 18.
5
MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.微小 RNA 连接乳腺癌中的雌激素受体 α 状态和 Dicer 水平。
Horm Cancer. 2010 Dec;1(6):306-19. doi: 10.1007/s12672-010-0043-5.
6
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.miR-221/222 靶向 TRPS1 促进乳腺癌上皮间质转化。
Sci Signal. 2011 Jun 14;4(177):ra41. doi: 10.1126/scisignal.2001538.
7
Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs.MCF-7 细胞的延长型乳腺球体培养诱导 EMT 并通过 microRNAs 抑制雌激素受体。
Breast Cancer Res Treat. 2012 Feb;132(1):75-85. doi: 10.1007/s10549-011-1534-y. Epub 2011 May 7.
8
MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer.三阴性(ER、PR 和 Her2/neu)乳腺癌中的 microRNA 表达分析。
Cell Cycle. 2011 Feb 1;10(3):507-17. doi: 10.4161/cc.10.3.14754.
9
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.MicroRNA-221/222 通过调节多种信号通路赋予乳腺癌氟维司群耐药性。
Oncogene. 2011 Mar 3;30(9):1082-97. doi: 10.1038/onc.2010.487. Epub 2010 Nov 8.
10
PUMA is a novel target of miR-221/222 in human epithelial cancers.PUMA 是人类上皮性癌症中 miR-221/222 的一个新靶点。
Int J Oncol. 2010 Dec;37(6):1621-6. doi: 10.3892/ijo_00000816.